

CITATION REPORT

List of articles citing

Clinical pharmacokinetics of pravastatin

DOI: 10.2165/00003088-199427020-00002
Clinical Pharmacokinetics, 1994, 27, 94-103.

Source: <https://exaly.com/paper-pdf/25418531/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
61	Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 604-9	2.9	74
60	Effect of age and gender on pharmacokinetics of atorvastatin in humans. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 242-6	2.9	67
59	Use of HMG-CoA Reductase Inhibitors after Kidney and Heart Transplantation: Lipid-Lowering and Immunosuppressive Effects. <i>BioDrugs</i> , 1997 , 8, 387-93	7.9	10
58	Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 403-25	6.2	379
57	Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 210-58	6.2	543
56	Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 311-21	6.1	136
55	Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. 1998 , 80, 1-34		185
54	Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. <i>Fundamental and Clinical Pharmacology</i> , 1999 , 13, 232-6	3.1	17
53	New insights into the pharmacodynamic and pharmacokinetic properties of statins. 1999 , 84, 413-28		592
52	Effects of food on clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1999 , 37, 213-55	6.2	249
51	Fire and forget?T- pharmacological considerations in coronary care. <i>Atherosclerosis</i> , 1999 , 147 Suppl 1, S23-30	3.1	15
50	Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000 , 23, 851-66	3.5	48
49	Author's Reply. <i>Annals of Pharmacotherapy</i> , 2000 , 34, 538-541	2.9	
48	Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 316-23	2.9	73
47	Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 397-412	6.2	151
46	Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. <i>Drugs</i> , 2000 , 60, 1179-206	12.1	20
45	Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin. <i>Clinical Drug Investigation</i> , 2000 , 19, 71-73	3.2	8

44	Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 835-45	2.9	64
43	Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 343-70	6.2	305
42	Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 793, 193-205	3.2	56
41	The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. <i>Drugs</i> , 2003 , 63, 139-52	12.1	38
40	Pravastatin: a review of its use in elderly patients. <i>Drugs and Aging</i> , 2003 , 20, 1061-82	4.7	5
39	Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. <i>Expert Opinion on Drug Safety</i> , 2003 , 2, 269-86	4.1	15
38	[Establishment and effect of the drug safety management monitoring system]. <i>Yakugaku Zasshi</i> , 2003 , 123, 893-900	0	2
37	Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. <i>Journal of Cellular Biochemistry</i> , 2004 , 93, 917-28	4.7	40
36	Pharmacokinetic parameter prediction from drug structure using artificial neural networks. <i>International Journal of Pharmaceutics</i> , 2004 , 270, 209-19	6.5	60
35	Development of Electrochemical Methods for Determination of Atorvastatin and Analytical Application to Pharmaceutical Products and Spiked Human Plasma. <i>Critical Reviews in Analytical Chemistry</i> , 2004 , 34, 1-7	5.2	28
34	Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 977-89	5.6	81
33	Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. <i>Fundamental and Clinical Pharmacology</i> , 2005 , 19, 117-25	3.1	725
32	Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. <i>Psychosomatics</i> , 2005 , 46, 565-8	2.6	19
31	Statins dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. <i>International Journal of Cardiology</i> , 2005 , 101, 9-17	3.2	52
30	Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. <i>Current Therapeutic Research</i> , 2005 , 66, 238-46	2.4	4
29	[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. <i>Presse Medicale</i> , 2006 , 35, 219-29	2.2	2
28	Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals. <i>International Immunopharmacology</i> , 2006 , 6, 53-60	5.8	16
27	Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. <i>Biomedical Chromatography</i> , 2006 , 20, 282-93	1.7	74

26	Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. <i>Xenobiotica</i> , 2007 , 37, 416-26	2	53
25	Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. <i>Xenobiotica</i> , 2007 , 37, 474-86	2	47
24	Simvastatin regulates oligodendroglial process dynamics and survival. <i>Glia</i> , 2007 , 55, 130-43	9	74
23	Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. <i>Glia</i> , 2008 , 56, 954-62	9	37
22	Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. <i>Journal of Neuroscience</i> , 2009 , 29, 13543-56	6.6	137
21	Simvastatin and lovastatin, but not pravastatin, interact with MDR1. <i>Journal of Pharmacy and Pharmacology</i> , 2002 , 54, 419-23	4.8	42
20	Pravastatin treatment causes a shift in the balance of hippocampal neurotransmitter binding densities towards inhibition. <i>Brain Research</i> , 2010 , 1316, 17-26	3.7	3
19	Statins improve visual field alterations related to hypercholesterolemia. <i>Atherosclerosis</i> , 2010 , 209, 510-4	4.1	4
18	Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. <i>Annals of Clinical Biochemistry</i> , 2011 , 48, 75-8	2.2	6
17	Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin. <i>Indian Journal of Pharmacology</i> , 2012 , 44, 624-8	2.5	6
16	High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. <i>Journal of Pharmaceutical Analysis</i> , 2012 , 2, 206-213	14	21
15	Assaying embryotoxicity in the test tube: current limitations of the embryonic stem cell test (EST) challenging its applicability domain. <i>Critical Reviews in Toxicology</i> , 2012 , 42, 443-64	5.7	31
14	Pharmacological actions of statins: a critical appraisal in the management of cancer. <i>Pharmacological Reviews</i> , 2012 , 64, 102-46	22.5	303
13	Effects of bile salts on gastrointestinal absorption of pravastatin. <i>Journal of Pharmaceutical Sciences</i> , 2012 , 101, 2281-7	3.9	7
12	Molecular mechanisms underlying the effects of statins in the central nervous system. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 20607-37	6.3	94
11	The effect of simvastatin and pravastatin on arterial blood pressure, baroreflex, vasoconstrictor, and hypertensive effects of angiotensin II in Sprague-Dawley rats. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 863-71		6
10	Pravastatin sodium. <i>Profiles of Drug Substances, Excipients and Related Methodology</i> , 2014 , 39, 433-513	3	4
9	Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. <i>International Journal of Pharmaceutics</i> , 2015 , 483, 77-88	6.5	33

8	Duodenum-triggered delivery of pravastatin sodium: II. Design, appraisal and pharmacokinetic assessments of enteric surface-decorated nanocubosomal dispersions. <i>Drug Delivery</i> , 2016 , 23, 3266-3278	7	11
7	Statins inhibit blastocyst formation by preventing geranylgeranylation. <i>Molecular Human Reproduction</i> , 2016 , 22, 350-63	4.4	13
6	Implications of cerebrovascular ATP-binding cassette transporter G1 (ABCG1) and apolipoprotein M in cholesterol transport at the blood-brain barrier. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017 , 1862, 573-588	5	24
5	Anti-TNF effect of combined pravastatin and cilostazol treatment in a mouse model. <i>Immunopharmacology and Immunotoxicology</i> , 2019 , 41, 179-184	3.2	3
4	Spray-dried pH-sensitive microparticles: effectual methodology to ameliorate the bioavailability of acid labile pravastatin. <i>Drug Development and Industrial Pharmacy</i> , 2019 , 45, 485-497	3.6	0
3	Detection of 4a,5-dihydropravastatin as Impurity in the Cholesterol Lowering Drug Pravastatin. <i>Molecules</i> , 2021 , 26,	4.8	
2	Statins and the Brain: More than Lipid Lowering Agents?. <i>Current Neuropharmacology</i> , 2019 , 17, 59-83	7.6	39
1	Pravastatin. 2007 , 1-4		